The P.R.R. for pancreatic cancers of glipizide, gliclazide, and nateglinide appears to be inversely correlated with their IC50 to block the recombinant Kir6.2-Sur1 subunits with the glipizide, gliclazide, and nateglinide showing the highest cancer risk and the lowest hypoglycemia risk (Figure 6) within the KATP channel blockers including zoledronic acid. This evidence concerns the gene ABCC8 and cancer.